Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 24;109(8):2469–2477. doi: 10.3324/haematol.2024.285225

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2024 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 1. — Overall survival of patients in the SAL and TriNetX cohort. (A) Overall survival (OS) of patients in the Study Alliance Leukemia (SAL) cohort calculated from diagnosis of acute myeloid leukemia (AML). Median OS was 7.7 (95% confidence interval [CI]: 5.3-12) months in the time from diagnosis to treatment (TDT) 0-9 and 9.6 (95% CI: 6.4- not reached) months in the TDT ≥10 group (P=0.42). Median follow-up time was 16 and 12 months, respectively. (B) OS of patients in the TriNetX-cohort calculated from diagnosis of AML. Median OS was 7.5 (95% CI: 5.8-8.6) months in the TDT 0-9 group and 7.2 (95% CI: 5.5-7.9) months in the TDT ≥10 group (P=0.41). Median follow-up time was 11 months in the whole cohort.